6-24806047-T-C
Variant names:
Variant summary
Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBS1BS2
The NM_001286445.3(RIPOR2):c.*326A>G variant causes a 3 prime UTR change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00768 in 245,256 control chromosomes in the GnomAD database, including 17 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).
Frequency
Genomes: 𝑓 0.011 ( 17 hom., cov: 32)
Exomes 𝑓: 0.0026 ( 0 hom. )
Consequence
RIPOR2
NM_001286445.3 3_prime_UTR
NM_001286445.3 3_prime_UTR
Scores
2
Clinical Significance
Conservation
PhyloP100: 0.547
Publications
2 publications found
Genes affected
RIPOR2 (HGNC:13872): (RHO family interacting cell polarization regulator 2) This gene encodes an atypical inhibitor of the small G protein RhoA. Inhibition of RhoA activity by the encoded protein mediates myoblast fusion and polarization of T cells and neutrophils. The encoded protein is a component of hair cell stereocilia that is essential for hearing. A splice site mutation in this gene results in hearing loss in human patients. [provided by RefSeq, Sep 2016]
RIPOR2 Gene-Disease associations (from GenCC):
- autosomal recessive nonsyndromic hearing loss 104Inheritance: AR Classification: MODERATE, LIMITED Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics, PanelApp Australia
- nonsyndromic genetic hearing lossInheritance: AR Classification: MODERATE Submitted by: ClinGen
- hearing loss, autosomal recessiveInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- autosomal dominant nonsyndromic hearing loss 21Inheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -20 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.88).
BP6
Variant 6-24806047-T-C is Benign according to our data. Variant chr6-24806047-T-C is described in ClinVar as [Likely_benign]. Clinvar id is 1316858.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BS1
Variant frequency is greater than expected in population afr. GnomAd4 allele frequency = 0.0108 (1642/152220) while in subpopulation AFR AF = 0.0312 (1295/41528). AF 95% confidence interval is 0.0298. There are 17 homozygotes in GnomAd4. There are 800 alleles in the male GnomAd4 subpopulation. Median coverage is 32. This position passed quality control check.
BS2
High Homozygotes in GnomAd4 at 17 AR,AD gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RIPOR2 | NM_001286445.3 | c.*326A>G | 3_prime_UTR_variant | Exon 22 of 22 | ENST00000643898.2 | NP_001273374.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RIPOR2 | ENST00000643898.2 | c.*326A>G | 3_prime_UTR_variant | Exon 22 of 22 | NM_001286445.3 | ENSP00000494268.2 | ||||
ENSG00000282804 | ENST00000562221.1 | c.*6+320A>G | intron_variant | Intron 2 of 2 | 5 | ENSP00000455145.1 |
Frequencies
GnomAD3 genomes AF: 0.0107 AC: 1623AN: 152102Hom.: 17 Cov.: 32 show subpopulations
GnomAD3 genomes
AF:
AC:
1623
AN:
152102
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.00259 AC: 241AN: 93036Hom.: 0 Cov.: 0 AF XY: 0.00249 AC XY: 120AN XY: 48118 show subpopulations
GnomAD4 exome
AF:
AC:
241
AN:
93036
Hom.:
Cov.:
0
AF XY:
AC XY:
120
AN XY:
48118
show subpopulations
African (AFR)
AF:
AC:
44
AN:
2200
American (AMR)
AF:
AC:
9
AN:
1738
Ashkenazi Jewish (ASJ)
AF:
AC:
7
AN:
3126
East Asian (EAS)
AF:
AC:
1
AN:
4048
South Asian (SAS)
AF:
AC:
26
AN:
10230
European-Finnish (FIN)
AF:
AC:
5
AN:
5184
Middle Eastern (MID)
AF:
AC:
9
AN:
470
European-Non Finnish (NFE)
AF:
AC:
117
AN:
59846
Other (OTH)
AF:
AC:
23
AN:
6194
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.498
Heterozygous variant carriers
0
12
23
35
46
58
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
GnomAD4 genome AF: 0.0108 AC: 1642AN: 152220Hom.: 17 Cov.: 32 AF XY: 0.0107 AC XY: 800AN XY: 74422 show subpopulations
GnomAD4 genome
AF:
AC:
1642
AN:
152220
Hom.:
Cov.:
32
AF XY:
AC XY:
800
AN XY:
74422
show subpopulations
African (AFR)
AF:
AC:
1295
AN:
41528
American (AMR)
AF:
AC:
122
AN:
15288
Ashkenazi Jewish (ASJ)
AF:
AC:
13
AN:
3470
East Asian (EAS)
AF:
AC:
11
AN:
5168
South Asian (SAS)
AF:
AC:
26
AN:
4826
European-Finnish (FIN)
AF:
AC:
2
AN:
10612
Middle Eastern (MID)
AF:
AC:
4
AN:
294
European-Non Finnish (NFE)
AF:
AC:
143
AN:
68012
Other (OTH)
AF:
AC:
21
AN:
2110
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.503
Heterozygous variant carriers
0
88
176
265
353
441
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
30
AN:
3478
ClinVar
Significance: Likely benign
Submissions summary: Benign:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Benign:2
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:not provided
- -
Jan 16, 2019
GeneDx
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.